Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies.
Tura
S
S
Mazza
P
P
Gherlinzoni
F
F
Zinzani
P L
PL
Poletti
G
G
Visani
G
G
Lemoli
R M
RM
Bandini
G
G
Cavo
M
M
Galieni
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C038259:ambamustine